A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms

The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.

本研究旨在探讨：将新近获批用于治疗膀胱过度活动症（overactive bladder）的新型药物米拉贝隆（mirabegron），加入至索利那新（solifenacin）这一抗毒蕈碱治疗（antimuscarinic treatment）方案中，是否较单独使用索利那新治疗更能有效控制尿失禁。